Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
$KPRX
Biotechnology: Pharmaceutical Preparations
Health Care
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/19/2022 | $2.50 | Buy | Maxim Group |
HC Wainwright & Co. analyst Yi Chen maintains Kiora Pharmaceuticals (NASDAQ:KPRX) with a Buy, adjusts target to $10 from $2 (1-9 Reverse Stock Split).
8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
10-Q - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
Encinitas, California--(Newsfile Corp. - April 21, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) has appointed Mark Pennesi, M.D., Ph.D., the Kenneth C. Swan Endowed Professor in Ophthalmology and Molecular and Medical Genetics and the Chief of the Paul H. Casey Ophthalmic Genetics Division at the Casey Eye Institute at Oregon Health & Science University, to their Scientific Advisory Board. As a member of the Scientific Advisory Board, his expertise and insights will contribute to the company's development of new treatments and therapies for patients suffering from eye diseases, including retinitis pigmentosa, a rare inherited degenerative eye disease in which Kiora is enrolling a clinical tri
Salt Lake City, Utah--(Newsfile Corp. - September 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) ("Kiora" or the "Company") has appointed Melissa Tosca as Executive Vice President of Finance. Mrs. Tosca will join the executive management team and oversee finance, SEC reporting and accounting functions as well as play a role in the company's capital markets strategy and planning. "Melissa brings to our company more than 15 years of financial and operational experience in both clinical and commercial-stage biotech and life science companies," said Brian M. Strem, Ph.D., President and CEO of Kiora. "This experience will be invaluable to our goals of advancing our development pipeline and
Salt Lake City, Utah--(Newsfile Corp. - February 1, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), ("Kiora" or the "Company") announced today the appointment of Erin Parsons as a new independent Director of its Board of Directors (the "Board"). Separately, the Executive Chairman, Stephen From, has informed Kiora of his voluntary resignation from the Board. These changes are effective immediately. "I am pleased to welcome Erin Parsons to our Board of Directors," said Brian M. Strem, Ph.D, President and CEO of Kiora. "Erin brings extensive commercial and strategic expertise in eyecare, a critical and complementary perspective as we continue to dedicate efforts to develop therapeutics for e
Amendment eliminates $4.75M in near-term milestones Kiora would have owed to SentrxSentrx gains access to Kiora's recently issued patents covering the combination of KIO-201 and antibiotics for veterinary useKiora will receive a royalty on net sales of products covered by licensed patentsEncinitas, California--(Newsfile Corp. - June 15, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) ("Kiora") and Sentrx Animal Care ("Sentrx") announced today they have amended their existing licensing agreement for patents and technology related to Kiora's KIO-201 product candidate. The amended agreement between the companies eliminates up to $4.75M in near-term financial payments by Kiora to Sentrx that w
Encinitas, California--(Newsfile Corp. - May 9, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) announced its first quarter 2023 results, during which time it significantly advanced its ocular drug development pipeline of clinical-stage candidates for the treatment of Retinitis Pigmentosa (RP), Persistent Corneal Epithelial Defects (PCEDs), and the Ocular Presentation of Rheumatoid Arthritis (OPRA).CEO Commentary"This has been a pivotal quarter for our business resulting in several recently reported clinical development milestones," said Brian M. Strem, Ph.D., president and CEO of Kiora. "Last month we reported preliminary results from our open-label study of KIO-301, our flagship asset, demonst
Encinitas, California--(Newsfile Corp. - May 1, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) announced today an encore presentation on KIO-301 neuroimaging results at The American Society of Neuroradiology 2023 Meeting in Chicago. The late-breaking abstract presentation titled "Functional Vision Reanimation in Retinitis Pigmentosa using an Intravitreal 'Photoswitch' Molecule (KIO-301): Functional MRI Protocol and Preliminary In-Human Observations" will be presented by Christen Barras, MBBS, Ph.D., Neuroradiologist at Jones Radiology, Associate Professor of Radiology at the University of Adelaide, in Adelaide, Australia and a co-investigator in the study.Patients with Retinitis Pigmentosa (RP)
SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)
SC 13G - KIORA PHARMACEUTICALS INC (0001372514) (Subject)
SC 13G - KIORA PHARMACEUTICALS INC (0001372514) (Subject)
4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
Maxim Group initiated coverage of Kiora Pharmaceuticals with a rating of Buy and set a new price target of $2.50